Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
Rhea-AI Summary
Viking Therapeutics (NASDAQ: VKTX) will release first-quarter 2026 financial results after market close on Wednesday, April 29, 2026. A conference call to discuss results and corporate updates will begin at 4:30 p.m. ET the same day.
Live webcast access is available via Viking's Webcasts page. A telephone replay is accessible until May 6, 2026, and an archived webcast will remain on the Webcasts page for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – VKTX
In the Apr 23 session, VKTX declined 4.23%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Earnings date notice | Neutral | -11.1% | Set date and call details for Q4 and year-end 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The last similar earnings-date notice on Feb 4, 2026 was followed by a -11.06% move, signaling the market has reacted sharply around scheduling headlines in the past.
This announcement sets the timetable for Viking’s Q1 2026 results, echoing the prior earnings-date release on Feb 4, 2026 for Q4 and year-end 2025. That earlier notice preceded a -11.06% move, while subsequent filings highlighted a larger 2025 net loss and intensified R&D investment alongside strong obesity and NASH/MASH data. Today’s headline continues the pattern of clearly flagging upcoming results and conference call logistics for investors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time
The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 29, 2026. To participate on the conference call, please dial (844) 850-0543 from the
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-first-quarter-2026-on-april-29-2026-302750792.html
SOURCE Viking Therapeutics, Inc.